@cellowaiter68
Active 3 years, 7 months ago
008); alemtuzumab individuals showed better 5-year flexibility through each result (30%182%/86%/54%) compared to Thymoglobulin (20%154%/62%/27%), daclizumab (19%/55%/70%/43%), and no-induction organizations (18%/70%/69%/46%). The groups did not differ inside PTLD rates (>Is equal to 94% free of PTLD from A few years; g Equates to 0.864). […] View
Events
Events I'm Attending
Not attending any events yet.

